Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.
This study is ongoing, but not recruiting participants.
Study NCT00337389 Information provided by Adventrx Pharmaceuticals
First Received: June 14, 2006 Last Updated: November 15, 2007
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Metastatic Colorectal Cancer
Colon Cancer
Rectal Cancer
Additional conditions recognized in this trial
Colonic Neoplasms
Colorectal Neoplasms
Rectal Neoplasms
More general conditions related to this trial
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms
Neoplasms by Site
Rectal Diseases
Interventions listed in this trial
5- Fluorouracil (5-FU)
bevacizumab (Avastin)
Leucovorin
CoFactor (ANX-510)
Additional drug interventions recognized in this trial
Bevacizumab
Fluorouracil
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Micronutrients
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Vitamin B Complex
Vitamins
Sponsors listed in this trial
Adventrx Pharmaceuticals
Back to top of Main Content
